Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALM-701
- Development stage
- Preclinical
- Lead developer
- Almac Discovery
- Modality
- Small Molecules
01
Overview
ALM-701 is a small molecule inhibitor of Ubiquitin Specific Peptidase 7 (USP7) currently in preclinical development by Almac Discovery. USP7 is a deubiquitinating enzyme (DUB) that plays a critical role in regulating the stability of various proteins, including those involved in viral replication and oncogenesis. By inhibiting USP7, ALM-701 aims to disrupt the survival and proliferation of Epstein-Barr Virus (EBV)-driven cancers, such as EBV-associated lymphomas and certain epithelial cancers, as well as other virally-driven malignancies. The program is part of Almac Discovery's internal pipeline focusing on deubiquitinase targets for oncology and other therapeutic areas.
02
Targets
USP7
Beyond the preview
Go deeper on ALM-701.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALM-701.